Modality
ERT
MOA
FXIai
Target
TIM-3
Pathway
Complement
RSV
Development Pipeline
Preclinical
~Mar 2017
→ ~Jun 2018
Phase 1
Sep 2018
→ Oct 2027
Phase 1Current
NCT08635068
446 pts·RSV
2018-09→2027-10·Recruiting
446 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2027-10-161.5y awayInterim· RSV
Trial Timeline
Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q4
P1
Recruit…
Catalysts
Interim
2027-10-16 · 1.5y away
RSV
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08635068 | Phase 1 | RSV | Recruiting | 446 | HAM-D |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| NVS-6360 | Novartis | Approved | CD38 | |
| MRK-3745 | Merck & Co | Phase 2 | WRN | |
| AZN-1715 | AstraZeneca | Phase 3 | AHR | |
| BMY-9931 | Bristol-Myers Squibb | Phase 1 | GPRC5D | |
| NVO-7877 | Novo Nordisk | Preclinical | GPRC5D | |
| TAK-8730 | Takeda | Phase 2 | VEGF | |
| REG-6699 | Regeneron | Phase 2/3 | TIM-3 | |
| Semazasiran | BeiGene | Phase 1 | PD-1 | |
| Nidasacituzumab | United Therapeutics | Phase 1/2 | TIM-3 | |
| Pexanesiran | United Therapeutics | Phase 1 | BCMA |